300439 美康生物
交易中 01-13 14:47:48
资讯
新帖
简况
美康生物（300439）披露取得两项医疗器械注册证，1月9日股价上涨0.49%
证券之星 · 01-09
美康生物（300439）披露取得两项医疗器械注册证，1月9日股价上涨0.49%
美康生物(300439.SZ)取得两项医疗器械注册证
智通财经 · 01-09
美康生物(300439.SZ)取得两项医疗器械注册证
美康生物：公司密切关注AI技术在体外诊断领域的应用
证券之星 · 2025-12-26
美康生物：公司密切关注AI技术在体外诊断领域的应用
美康生物：公司主要从事体外诊断产品的研发、生产和销售
证券之星 · 2025-12-09
美康生物：公司主要从事体外诊断产品的研发、生产和销售
美康生物：截至2025年9月30日股东人数为23,895人
证券之星 · 2025-11-27
美康生物：截至2025年9月30日股东人数为23,895人
美康生物（300439）披露调整组织架构并修订公司章程议案获股东大会通过，11月14日股价上涨1.1%
证券之星 · 2025-11-14
美康生物（300439）披露调整组织架构并修订公司章程议案获股东大会通过，11月14日股价上涨1.1%
美康生物（300439）披露召开2025年第一次临时股东大会提示性公告，11月11日股价上涨0.47%
证券之星 · 2025-11-11
美康生物（300439）披露召开2025年第一次临时股东大会提示性公告，11月11日股价上涨0.47%
美康生物(300439.SZ)：肝素结合蛋白检测试剂盒(化学发光免疫分析法)取得医疗器械注册证
智通财经 · 2025-11-11
美康生物(300439.SZ)：肝素结合蛋白检测试剂盒(化学发光免疫分析法)取得医疗器械注册证
美康生物（300439）2025年三季报简析：净利润同比下降73.02%，公司应收账款体量较大
中金财经 · 2025-10-30
美康生物（300439）2025年三季报简析：净利润同比下降73.02%，公司应收账款体量较大
图解美康生物三季报：第三季度单季净利润同比下降91.94%
证券之星 · 2025-10-29
图解美康生物三季报：第三季度单季净利润同比下降91.94%
美康生物（300439）披露拟调整组织架构并修订公司章程，10月28日股价上涨0.19%
证券之星 · 2025-10-28
美康生物（300439）披露拟调整组织架构并修订公司章程，10月28日股价上涨0.19%
美康生物(300439.SZ)取得一项医疗器械注册证
智通财经 · 2025-09-26
美康生物(300439.SZ)取得一项医疗器械注册证
美康生物(300439.SZ)子公司取得多项医疗器械注册证
智通财经 · 2025-09-17
美康生物(300439.SZ)子公司取得多项医疗器械注册证
美康生物新注册《美智医学检查检验结果互认共享系统V1.0》项目的软件著作权
证券之星 · 2025-09-17
美康生物新注册《美智医学检查检验结果互认共享系统V1.0》项目的软件著作权
美康生物：截至2025年6月30日股东人数为25,679人
证券之星 · 2025-09-05
美康生物：截至2025年6月30日股东人数为25,679人
美康生物最新公告：控股子公司取得医疗器械注册证
证券之星 · 2025-09-04
美康生物最新公告：控股子公司取得医疗器械注册证
美康生物（300439）2025年中报简析：净利润同比下降68.15%，公司应收账款体量较大
证券之星 · 2025-08-30
美康生物（300439）2025年中报简析：净利润同比下降68.15%，公司应收账款体量较大
美康生物最新公告：公司及控股子公司取得医疗器械注册证
证券之星 · 2025-08-28
美康生物最新公告：公司及控股子公司取得医疗器械注册证
美康生物：深圳美康盛德生物科技有限公司从事体外诊断产品研发及国际贸易业务
证券之星 · 2025-08-21
美康生物：深圳美康盛德生物科技有限公司从事体外诊断产品研发及国际贸易业务
美康生物：体外诊断试剂毛利率低主要系产品结构影响
证券之星 · 2025-07-25
美康生物：体外诊断试剂毛利率低主要系产品结构影响
加载更多
公司概况
公司名称：
美康生物科技股份有限公司
所属行业：
医药制造业
上市日期：
2015-04-22
主营业务：
美康生物科技股份有限公司的主营业务是体外诊断产品的研发、生产和销售及体外诊断产品的代理业务，并提供第三方医学诊断服务。公司的主要产品是体外诊断试剂、体外诊断仪器、第三方医学诊断服务。
发行价格：
27.51
{"stockData":{"symbol":"300439","market":"SZ","secType":"STK","nameCN":"美康生物","latestPrice":10.45,"timestamp":1768286868000,"preClose":10.28,"halted":0,"volume":8857634,"delay":0,"changeRate":0.0165,"floatShares":292000000,"shares":384000000,"eps":0.2451,"marketStatus":"交易中","change":0.17,"latestTime":"01-13 14:47:48","open":10.3,"high":10.58,"low":10.27,"amount":92756800,"amplitude":0.0302,"askPrice":10.45,"askSize":39,"bidPrice":10.44,"bidSize":693,"shortable":0,"etf":0,"ttmEps":0.2451,"tradingStatus":2,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1768287600000},"marketStatusCode":2,"adr":0,"adjPreClose":10.28,"symbolType":"stock","openAndCloseTimeList":[[1768267800000,1768275000000],[1768280400000,1768287600000]],"highLimit":11.31,"lowLimit":9.25,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":384318815,"isCdr":false,"pbRate":1.34,"roa":"--","peRate":42.635659,"roe":"2.05%","epsLYR":0.67,"committee":0.440994,"marketValue":4016000000,"turnoverRate":0.0303,"status":0,"floatMarketCap":3055000000},"requestUrl":"/m/hq/s/300439","defaultTab":"news","newsList":[{"id":"2602372320","title":"美康生物（300439）披露取得两项医疗器械注册证，1月9日股价上涨0.49%","url":"https://stock-news.laohu8.com/highlight/detail?id=2602372320","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602372320?lang=zh_cn&edition=full","pubTime":"2026-01-09 22:49","pubTimestamp":1767970151,"startTime":"0","endTime":"0","summary":"截至2026年1月9日收盘，美康生物报收于10.19元，较前一交易日上涨0.49%，最新总市值为39.16亿元。该股当日开盘10.13元，最高10.2元，最低10.07元，成交额达4587.65万元，换手率为1.55%。公司近日发布公告称，美康生物科技股份有限公司近日取得国家药品监督管理局和浙江省药品监督管理局颁发的两项医疗器械注册证，分别为乙型肝炎病毒e抗体测定试剂盒和高尔基体蛋白73检测试剂盒，有效期均为2025年12月至2030年12月。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010900041395.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["09997","BK0239","BK1100","BK1574","BK0042","BK1583","BK0046","159883","BK1222","300439","09996"],"gpt_icon":0},{"id":"2602329468","title":"美康生物(300439.SZ)取得两项医疗器械注册证","url":"https://stock-news.laohu8.com/highlight/detail?id=2602329468","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602329468?lang=zh_cn&edition=full","pubTime":"2026-01-09 17:33","pubTimestamp":1767951193,"startTime":"0","endTime":"0","summary":"智通财经APP讯，美康生物(300439.SZ)公告，公司近日取得了由国家药品监督管理局、浙江省药品监督管理局颁发的《医疗器械注册证(体外诊断试剂)》，包括：乙型肝炎病毒e抗体测定试剂盒(化学发光微粒子免疫检测法)、高尔基体蛋白73检测试剂盒(化学发光微粒子免疫检测法)。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1390981.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09996","BK1574","BK0042","09997","BK1583","300439","BK0046","BK1100","BK0239","159883","BK1222"],"gpt_icon":0},{"id":"2594829981","title":"美康生物：公司密切关注AI技术在体外诊断领域的应用","url":"https://stock-news.laohu8.com/highlight/detail?id=2594829981","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594829981?lang=zh_cn&edition=full","pubTime":"2025-12-26 20:51","pubTimestamp":1766753495,"startTime":"0","endTime":"0","summary":"证券之星消息，美康生物(300439)12月25日在投资者关系平台上答复投资者关心的问题。投资者提问：如今AI模型及应用在医学方向落地有很好的基础，公司是否考虑储备并基于AI的模型做进阶的诊疗服务呢？这个未来应该是很有竞争力的方向。另外公司对市值管理重视程度不够，通过提升公司市值，可以侧面宣传公司的形象，提升公司知名度，而不是留下一个10年跌去90%市值的口实。美康生物回复：尊敬的投资者您好！非常感谢您的建议，公司密切关注AI技术在体外诊断领域的应用。谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122600033268.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300439","BK0046","BK0239","BK0042"],"gpt_icon":0},{"id":"2590336717","title":"美康生物：公司主要从事体外诊断产品的研发、生产和销售","url":"https://stock-news.laohu8.com/highlight/detail?id=2590336717","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590336717?lang=zh_cn&edition=full","pubTime":"2025-12-09 08:42","pubTimestamp":1765240930,"startTime":"0","endTime":"0","summary":"证券之星消息，美康生物12月08日在投资者关系平台上答复投资者关心的问题。同行业的热景生物创新药翻了十倍，浩欧博借壳也十倍，公司股价相对于最高点只剩一折，不该知耻而后勇吗？！公司主要从事体外诊断产品的研发、生产和销售及体外诊断产品的代理业务，并提供第三方医学诊断服务。未来如有创新药方面的布局，将严格按照有关法律法规的规定和要求及时履行信息披露义务，感谢您的建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120900004667.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300439","BK0042","BK0239","BK0046"],"gpt_icon":0},{"id":"2586294540","title":"美康生物：截至2025年9月30日股东人数为23,895人","url":"https://stock-news.laohu8.com/highlight/detail?id=2586294540","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586294540?lang=zh_cn&edition=full","pubTime":"2025-11-27 08:54","pubTimestamp":1764204853,"startTime":"0","endTime":"0","summary":"证券之星消息，美康生物11月26日在投资者关系平台上答复投资者关心的问题。敬请发布截至今天10月31日公司的股东户数信息美康生物回复：尊敬的投资者您好！截至2025年9月30日，公司的股东人数为23,895人。如确需查询其他时点的股东人数，股东需提供身份证明文件以及相关持有公司股份的种类以及数量的书面文件，经公司核实相关信息后按规定办理及回复。公司联系邮箱mksw@nbmksw.com。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112700004346.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0042","BK0046","BK0239","300439"],"gpt_icon":0},{"id":"2583750212","title":"美康生物（300439）披露调整组织架构并修订公司章程议案获股东大会通过，11月14日股价上涨1.1%","url":"https://stock-news.laohu8.com/highlight/detail?id=2583750212","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583750212?lang=zh_cn&edition=full","pubTime":"2025-11-14 22:41","pubTimestamp":1763131282,"startTime":"0","endTime":"0","summary":"截至2025年11月14日收盘，美康生物报收于11.04元，较前一交易日上涨1.1%，最新总市值为42.43亿元。该股当日开盘10.85元，最高11.11元，最低10.84元，成交额达7729.49万元，换手率为2.4%。会议采用现场投票与网络投票相结合方式，出席股东109人，代表股份占公司有表决权股份总数的47.7012%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111400042040.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0046","300439","BK0042"],"gpt_icon":0},{"id":"2582936035","title":"美康生物（300439）披露召开2025年第一次临时股东大会提示性公告，11月11日股价上涨0.47%","url":"https://stock-news.laohu8.com/highlight/detail?id=2582936035","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582936035?lang=zh_cn&edition=full","pubTime":"2025-11-11 22:48","pubTimestamp":1762872504,"startTime":"0","endTime":"0","summary":"截至2025年11月11日收盘，美康生物报收于10.73元，较前一交易日上涨0.47%，最新总市值为41.24亿元。该股当日开盘10.66元，最高10.77元，最低10.6元，成交额达4348.62万元，换手率为1.39%。近日，美康生物科技股份有限公司发布关于召开2025年第一次临时股东大会的提示性公告。公告称，公司将于2025年11月14日召开2025年第一次临时股东大会，会议将采用现场与网络投票相结合的方式进行。股权登记日为2025年11月7日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111100041280.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0042","300439","BK0239","BK0046"],"gpt_icon":0},{"id":"2582351760","title":"美康生物(300439.SZ)：肝素结合蛋白检测试剂盒(化学发光免疫分析法)取得医疗器械注册证","url":"https://stock-news.laohu8.com/highlight/detail?id=2582351760","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582351760?lang=zh_cn&edition=full","pubTime":"2025-11-11 17:11","pubTimestamp":1762852285,"startTime":"0","endTime":"0","summary":"智通财经APP讯，美康生物(300439.SZ)发布公告，近日，公司的控股子公司江西美康盛德生物科技有限公司(以下简称“江西美康”)取得了由江西省药品监督管理局颁发的《中华人民共和国医疗器械注册证(体外诊断试剂)》，涉及产品：“肝素结合蛋白检测试剂盒(化学发光免疫分析法)”。上述《注册证》的取得，丰富了公司在体外诊断化学发光细分领域产品线的品种，有利于进一步提升公司的核心竞争力和市场拓展能力，对公司未来的经营将产生积极影响。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1367792.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["159883","BK1583","BK0239","BK1100","09997","BK1574","BK0042","BK1222","300439","BK0046","09996"],"gpt_icon":0},{"id":"2579783156","title":"美康生物（300439）2025年三季报简析：净利润同比下降73.02%，公司应收账款体量较大","url":"https://stock-news.laohu8.com/highlight/detail?id=2579783156","media":"中金财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579783156?lang=zh_cn&edition=full","pubTime":"2025-10-30 08:06","pubTimestamp":1761782762,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期美康生物发布2025年三季报。截至本报告期末，公司营业总收入11.36亿元，同比下降19.27%，归母净利润6053.38万元，同比下降73.02%。按单季度数据看，第三季度营业总收入3.99亿元，同比下降12.71%，第三季度归母净利润370.01万元，同比下降91.94%。本报告期美康生物公司应收账款体量较大，当期应收账款占最新年报归母净利润比达222.79%。去年的净利率为15.08%，算上全部成本后，公司产品或服务的附加值高。","market":"sh","thumbnail":" http://caiji.3g.cnfol.com/colect/202510/30/20251030587688.png","type":0,"news_type":0,"thumbnails":[" http://caiji.3g.cnfol.com/colect/202510/30/20251030587688.png"],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushiyaowen/20251030/31748828.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["300439"],"gpt_icon":0},{"id":"2579899536","title":"图解美康生物三季报：第三季度单季净利润同比下降91.94%","url":"https://stock-news.laohu8.com/highlight/detail?id=2579899536","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579899536?lang=zh_cn&edition=full","pubTime":"2025-10-29 02:55","pubTimestamp":1761677701,"startTime":"0","endTime":"0","summary":"证券之星消息，美康生物2025年三季报显示，公司主营收入11.36亿元，同比下降19.27%；归母净利润6053.38万元，同比下降73.02%；扣非净利润3120.67万元，同比下降83.86%；其中2025年第三季度，公司单季度主营收入3.99亿元，同比下降12.71%；单季度归母净利润370.01万元，同比下降91.94%；单季度扣非净利润118.21万元，同比下降97.25%；负债率19.34%，投资收益237.23万元，财务费用-186.97万元，毛利率39.64%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102900003253.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300439"],"gpt_icon":0},{"id":"2578696585","title":"美康生物（300439）披露拟调整组织架构并修订公司章程，10月28日股价上涨0.19%","url":"https://stock-news.laohu8.com/highlight/detail?id=2578696585","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578696585?lang=zh_cn&edition=full","pubTime":"2025-10-28 22:23","pubTimestamp":1761661395,"startTime":"0","endTime":"0","summary":"截至2025年10月28日收盘，美康生物报收于10.51元，较前一交易日上涨0.19%，最新总市值为40.39亿元。该股当日开盘10.48元，最高10.55元，最低10.42元，成交额达3832.71万元，换手率为1.25%。根据公司近日发布的第五届监事会第十五次会议决议公告，美康生物于2025年10月28日召开会议，审议通过《关于调整组织架构并修订<公司章程>的议案》。此外，董事会席位结构将调整为增加一名职工代表董事。该议案尚需提交公司2025年第一次临时股东大会审议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102800043110.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","300439","BK0239","BK0042"],"gpt_icon":0},{"id":"2570009072","title":"美康生物(300439.SZ)取得一项医疗器械注册证","url":"https://stock-news.laohu8.com/highlight/detail?id=2570009072","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2570009072?lang=zh_cn&edition=full","pubTime":"2025-09-26 17:50","pubTimestamp":1758880238,"startTime":"0","endTime":"0","summary":"智通财经APP讯，美康生物(300439.SZ)公告，公司近日取得了由浙江省药品监督管理局颁发的《医疗器械注册证(体外诊断试剂)》，产品名称为抗Xa检测试剂盒(发色底物法)。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1349940.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0042","159883","09996","300439","BK1583","BK1100","09997","BK1222","BK0046","BK0239","BK1574"],"gpt_icon":0},{"id":"2568464097","title":"美康生物(300439.SZ)子公司取得多项医疗器械注册证","url":"https://stock-news.laohu8.com/highlight/detail?id=2568464097","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2568464097?lang=zh_cn&edition=full","pubTime":"2025-09-17 17:46","pubTimestamp":1758102384,"startTime":"0","endTime":"0","summary":"智通财经APP讯，美康生物(300439.SZ)公告，公司的控股子公司江西美康盛德生物科技有限公司(简称“江西美康”)取得了由江西省药品监督管理局颁发的《医疗器械注册证(体外诊断试剂)》，产品包括：组织型纤溶酶原激活剂-抑制剂1复合物检测试剂盒(化学发光免疫分析法)、凝血酶-抗凝血酶复合物检测试剂盒(化学发光免疫分析法)、血栓调节蛋白检测试剂盒(化学发光免疫分析法)、纤溶酶-α2纤溶酶抑制剂复合物检测试剂盒(化学发光免疫分析法)。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1346359.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09997","BK0239","BK0046","BK1583","BK1100","BK1574","BK1222","300439","159883","09996","BK0042"],"gpt_icon":0},{"id":"2568487173","title":"美康生物新注册《美智医学检查检验结果互认共享系统V1.0》项目的软件著作权","url":"https://stock-news.laohu8.com/highlight/detail?id=2568487173","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2568487173?lang=zh_cn&edition=full","pubTime":"2025-09-17 02:03","pubTimestamp":1758045800,"startTime":"0","endTime":"0","summary":"证券之星消息，近日美康生物（300439）新注册了《美智医学检查检验结果互认共享系统V1.0》项目的软件著作权。今年以来美康生物新注册软件著作权1个。结合公司2025年中报财务数据，今年上半年公司在研发方面投入了7145.12万元，同比减6.44%。通过天眼查大数据分析，美康生物科技股份有限公司共对外投资了35家企业，参与招投标项目853次；财产线索方面有商标信息226条，专利信息174条，著作权信息50条；此外企业还拥有行政许可199个。数据来源：天眼查APP以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025091700001256.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0046","300439","BK0042"],"gpt_icon":0},{"id":"2565458241","title":"美康生物：截至2025年6月30日股东人数为25,679人","url":"https://stock-news.laohu8.com/highlight/detail?id=2565458241","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2565458241?lang=zh_cn&edition=full","pubTime":"2025-09-05 09:03","pubTimestamp":1757034195,"startTime":"0","endTime":"0","summary":"证券之星消息，美康生物(300439)09月04日在投资者关系平台上答复投资者关心的问题。投资者提问：请问贵公司至8月31号股东户数是多少。美康生物回复：尊敬的投资者您好！公司会在定期报告中披露对应时点的股东信息。截至2025年6月30日，公司的股东人数为25,679人。如确需查询其他时点的股东人数，股东需提供身份证明文件以及相关持有公司股份的种类以及数量的书面文件，经公司核实相关信息后按规定办理及回复。公司联系邮箱mksw@nbmksw.com感谢您的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025090500007301.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0042","BK0046","300439"],"gpt_icon":0},{"id":"2564373382","title":"美康生物最新公告：控股子公司取得医疗器械注册证","url":"https://stock-news.laohu8.com/highlight/detail?id=2564373382","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2564373382?lang=zh_cn&edition=full","pubTime":"2025-09-04 18:01","pubTimestamp":1756980076,"startTime":"0","endTime":"0","summary":"美康生物(300439.SZ)公告称，公司控股子公司江西美康近日取得由江西省药品监督管理局颁发的医疗器械注册证，包括微量元素检测试剂盒（电感耦合等离子体质谱法）、微量元素质控品和尿酸/肌酐/尿素检测试剂盒（干化学法）。这些注册证的取得丰富了公司产品线，有利于提升核心竞争力和市场拓展能力，但实际销售情况取决于市场推广效果，对未来业绩的影响尚无法预测。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025090400028305.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1583","159883","09997","09996","BK0046","BK0239","BK1100","BK1574","300439","BK1222","BK0042"],"gpt_icon":0},{"id":"2563070173","title":"美康生物（300439）2025年中报简析：净利润同比下降68.15%，公司应收账款体量较大","url":"https://stock-news.laohu8.com/highlight/detail?id=2563070173","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2563070173?lang=zh_cn&edition=full","pubTime":"2025-08-30 06:28","pubTimestamp":1756506508,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期美康生物发布2025年中报。截至本报告期末，公司营业总收入7.36亿元，同比下降22.43%，归母净利润5683.37万元，同比下降68.15%。按单季度数据看，第二季度营业总收入3.62亿元，同比下降22.54%，第二季度归母净利润2643.6万元，同比下降73.4%。本报告期美康生物公司应收账款体量较大，当期应收账款占最新年报归母净利润比达209.1%。去年的净利率为15.08%，算上全部成本后，公司产品或服务的附加值高。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025083000011252.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300439"],"gpt_icon":0},{"id":"2562803402","title":"美康生物最新公告：公司及控股子公司取得医疗器械注册证","url":"https://stock-news.laohu8.com/highlight/detail?id=2562803402","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2562803402?lang=zh_cn&edition=full","pubTime":"2025-08-28 20:20","pubTimestamp":1756383643,"startTime":"0","endTime":"0","summary":"美康生物(300439.SZ)公告称，公司及控股子公司江西美康盛德生物科技有限公司近日取得多项医疗器械注册证，包括茶碱检测试剂盒（质谱法）、甲氨蝶呤检测试剂盒（液相色谱-串联质谱法）、甲氨蝶呤质控品及抑制素B检测试剂盒（化学发光免疫分析法）。这些注册证的取得将丰富公司在体外诊断化学发光及质谱细分领域产品线的品种，有利于提升公司的核心竞争力和市场拓展能力。然而，实际销售情况取决于未来市场推广效果，公司目前无法预测对未来业绩的具体影响，提醒投资者注意投资风险。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025082800040909.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","300439","BK0239","09996","BK0042","159883","BK1100","BK1222","BK1574","BK1583","09997"],"gpt_icon":0},{"id":"2561435757","title":"美康生物：深圳美康盛德生物科技有限公司从事体外诊断产品研发及国际贸易业务","url":"https://stock-news.laohu8.com/highlight/detail?id=2561435757","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2561435757?lang=zh_cn&edition=full","pubTime":"2025-08-21 08:57","pubTimestamp":1755737825,"startTime":"0","endTime":"0","summary":"证券之星消息，美康生物(300439)08月20日在投资者关系平台上答复投资者关心的问题。投资者提问：最近在大亚湾新开的子公司布局是什么方向的？医美？养老？养生保健？美康生物回复：尊敬的投资者您好！2025年公司在深圳市宝安区新设深圳美康盛德生物科技有限公司，主要从事体外诊断产品研发及国际贸易业务。感谢您的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025082100005441.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","159837","BK0239","300439","BK0042"],"gpt_icon":0},{"id":"2554758911","title":"美康生物：体外诊断试剂毛利率低主要系产品结构影响","url":"https://stock-news.laohu8.com/highlight/detail?id=2554758911","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2554758911?lang=zh_cn&edition=full","pubTime":"2025-07-25 11:36","pubTimestamp":1753414578,"startTime":"0","endTime":"0","summary":"证券之星消息，美康生物07月24日在投资者关系平台上答复投资者关心的问题。按产品类型分类，2024年度，公司体外诊断试剂收入11.64亿元，毛利率为49.32%，包括自产试剂以及代理试剂。自产产品毛利率高于代理产品毛利率，公司体外诊断试剂毛利率低主要系产品结构影响。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025072500015618.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300439","BK0046","BK0042"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1768286872635,"stockEarnings":[{"period":"1week","weight":0.0148},{"period":"1month","weight":0.0394},{"period":"3month","weight":0.0078},{"period":"6month","weight":-0.0705},{"period":"1year","weight":0.0741},{"period":"ytd","weight":0.0437}],"compareEarnings":[{"period":"1week","weight":0.0353},{"period":"1month","weight":0.0709},{"period":"3month","weight":0.0776},{"period":"6month","weight":0.1888},{"period":"1year","weight":0.3146},{"period":"ytd","weight":0.0495}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"美康生物科技股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"23895人(较上一季度减少6.95%)","perCapita":"12234股","listingDate":"2015-04-22","address":"浙江省宁波市鄞州区启明南路299号","registeredCapital":"38431万元","survey":" 美康生物科技股份有限公司的主营业务是体外诊断产品的研发、生产和销售及体外诊断产品的代理业务，并提供第三方医学诊断服务。公司的主要产品是体外诊断试剂、体外诊断仪器、第三方医学诊断服务。","listedPrice":27.51},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"美康生物(300439)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供美康生物(300439)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"美康生物,300439,美康生物股票,美康生物股票老虎,美康生物股票老虎国际,美康生物行情,美康生物股票行情,美康生物股价,美康生物股市,美康生物股票价格,美康生物股票交易,美康生物股票购买,美康生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"美康生物(300439)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供美康生物(300439)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}